Aclaris Therapeutics Inc.
| NASDAQ: ACRS | Healthcare / Biotechnology / USA |
| 1.98 | -0.0100 | -0.50% | Vol 374 999 | 1Y Perf -90.33% |
| Jul 22nd, 2019 16:00 |
| BID | 1.97 | ASK | 1.98 | ||
| Open | 2.00 | Previous Close | 1.99 | ||
| Pre-Market | - | After-Trading | 1.98 | ||
| - -% | - -% |
| Target Price | 24.60 | Analyst Rating | Strong Buy 1.40 | |
| Potencial % | 1 142.42 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12M | -100/-100/-70 | Value Ranking | — - | |
| Insiders Value % 3/6/12M | -100/-100/-30 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12M | -100/-100/-64 | Income Ranking | — - | |
| Market Cap (mil) | 82 | Earnings Rating | Sell | |
| Price Range Ratio 52wk % | 0.42 | Earnings Date | 2nd Aug 2019 |
Today's Price Range 1.902.06 | 52wk Range 1.9020.75 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -10.41% | ||
| 1 Month | -56.39% | ||
| 3 Months | -68.27% | ||
| 6 Months | -67.33% | ||
| 1 Year | -90.33% | ||
| 3 Years | -90.53% | ||
| 5 Years | - | ||
| 10 Years | - |
| Management Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Return on Equity (5Y Avg) | -23.31 | |||
ROE last 12 Months | -73.20 | |||
Return on Assets (5Y Avg) | -11.21 | |||
ROA last 12 Months | -59.13 | |||
Return on Capital (5Y Avg) | - | |||
ROC last 12 Months | -63.30 | |||
Return on invested Capital Q | -16.43 | |||
Return on invested Capital Y | -52.99 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 0.45 | |||
PS Ratio | 8.35 | |||
Price to Cash Flow | - | |||
Price to Free Cash Flow | -0.50 | |||
Cash Flow Per Share | -3.11 | |||
Price to Tangible Book | 0.89 | |||
Book Value per Share | 4.42 | |||
Enterprise Value (in ths.) | -24 705 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Quick Ratio | 4.20 | |||
Current Ratio | 4.30 | |||
Long Term Debt to Total Capital | 0.14 | |||
Total Debt to Equity | 0.16 | |||
Interest Coverage | - | |||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Gross Margin | 38.20 | |||
EBIT Margin | -1 001.10 | |||
EBITDA Margin | -973.40 | |||
Pre-tax Profit Margin | - | |||
Profit Margin | - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Revenue LTM (in ths.) | 9 838 | |||
Revenue per Share | 0.24 | |||
Revenue Growth 3 Years | - | |||
Revenue Growth 5 Years | - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2019 | -0.80 | -0.91 | -13.75 |
| Q04 2018 | -0.96 | -0.99 | -3.12 |
| Q03 2018 | -1.25 | -1.06 | 15.20 |
| Q02 2018 | -0.95 | -1.01 | -6.32 |
| Q01 2018 | -0.99 | -0.98 | 1.01 |
| Q04 2017 | -0.90 | -0.80 | 11.11 |
| Q03 2017 | -0.86 | -0.63 | 26.74 |
| Q02 2017 | -0.68 | -0.56 | 17.65 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2019 QR | -0.77 | -2.67 | Negative |
| 9/2019 QR | -0.72 | -4.35 | Negative |
| 12/2019 FY | -2.87 | 1.37 | Positive |
| 12/2020 FY | -2.33 | 7.91 | Positive |
| Next Report Date | 2nd Aug 2019 |
| Estimated EPS Next Report | -0.77 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 374 999 |
| Shares Outstanding (in ths.) | 41 272 |
| Trades Count | 1 633 |
| Dollar Volume | 677 988 |
| Avg. Volume | 603 800 |
| Avg. Weekly Volume | 344 515 |
| Avg. Monthly Volume | 1 152 949 |
| Avg. Quarterly Volume | 731 487 |
Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.
CEO: Neal Walker
Teplephone: +1 484 324-7933
Address: 640 Lee Road, Wayne 19087, PA, USA
